Pierre Triozzi to Recombinant Proteins
This is a "connection" page, showing publications Pierre Triozzi has written about Recombinant Proteins.
Connection Strength
0.892
-
Triozzi PL, Achberger S, Aldrich W, Elson P, Garcia J, Dreicer R. Differential immunologic and microRNA effects of 2 dosing regimens of recombinant human granulocyte/macrophage colony stimulating factor. J Immunother. 2012 Sep; 35(7):587-94.
Score: 0.403
-
Triozzi PL, Achberger S, Aldrich W, Singh AD, Grane R, Borden EC. The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon. J Transl Med. 2012 Dec 05; 10:241.
Score: 0.103
-
Triozzi PL, Aldrich W, Singh A. Effects of interleukin-1 receptor antagonist on tumor stroma in experimental uveal melanoma. Invest Ophthalmol Vis Sci. 2011 Jul 25; 52(8):5529-35.
Score: 0.093
-
Triozzi PL, Aldrich W. Effects of interleukin-1 receptor antagonist and chemotherapy on host-tumor interactions in established melanoma. Anticancer Res. 2010 Feb; 30(2):345-54.
Score: 0.084
-
Triozzi PL, Strong TV, Bucy RP, Allen KO, Carlisle RR, Moore SE, Lobuglio AF, Conry RM. Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma. Hum Gene Ther. 2005 Jan; 16(1):91-100.
Score: 0.059
-
Triozzi PL, Kim J, Aldrich W. Infusion of unpulsed dendritic cells derived from granulocyte/macrophage colony-stimulating factor-mobilized peripheral blood CD34+ cells and monocytes in patients with advanced carcinoma. J Hematother Stem Cell Res. 2003 Jun; 12(3):279-87.
Score: 0.053
-
Garcia JA, Elson P, Tyler A, Triozzi P, Dreicer R. Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial. Urol Oncol. 2014 Jan; 32(1):33.e11-7.
Score: 0.026
-
Yi T, Elson P, Mitsuhashi M, Jacobs B, Hollovary E, Budd TG, Spiro T, Triozzi P, Borden EC. Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects. Oncotarget. 2011 Dec; 2(12):1155-64.
Score: 0.024
-
Garcia JA, Klein EA, Magi-Galluzzi C, Elson P, Triozzi P, Dreicer R. Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma. Clin Cancer Res. 2008 May 15; 14(10):3052-9.
Score: 0.019
-
Neidhart J, Allen KO, Barlow DL, Carpenter M, Shaw DR, Triozzi PL, Conry RM. Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor. Vaccine. 2004 Jan 26; 22(5-6):773-80.
Score: 0.014
-
Korokhov N, Mikheeva G, Krendelshchikov A, Belousova N, Simonenko V, Krendelshchikova V, Pereboev A, Kotov A, Kotova O, Triozzi PL, Aldrich WA, Douglas JT, Lo KM, Banerjee PT, Gillies SD, Curiel DT, Krasnykh V. Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge. J Virol. 2003 Dec; 77(24):12931-40.
Score: 0.014